Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback